^
    Back
    Association details:
    Biomarker:MSH2 mutation
    Cancer:Adrenal Cortex Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Medicine (Baltimore)
    Title:

    Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden

    Excerpt:
    ...lesion identified mutations on the following genes: MSH2, ATM, APC, DAXX, KDM5LC...PD-L1 expression was 10%. Tumor mutational burden was 32.65 mutations/Mb...decision was made to start pembrolizumab (100 mg every 3 weeks), and a complete radiologic and metabolic response was detected after 5 cycles...Patient is currently on follow-up without any evidence of relapse...
    DOI:
    10.1097/MD.0000000000013517